Works by Holen, Kyle

Results: 50

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.

Published in:

2017

By:

Munasinghe, Wijith;
Mittapalli, Rajendar;
Li, Hong;
Hoffman, David;
Holen, Kyle;
Menon, Rajeev;
Xiong, Hao;
Munasinghe, Wijith P;
Mittapalli, Rajendar K;
Hoffman, David M;
Holen, Kyle D;
Menon, Rajeev M

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Kirschbrown, Whitney;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Waring, Jeffrey;
Yang, Jianning;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Waring, Jeffrey F;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.

Published in:

2015

By:

Sharma, Shringi;
Mittapalli, Rajendar;
Holen, Kyle;
Xiong, Hao;
Mittapalli, Rajendar K;
Holen, Kyle D

Publication type:

journal article

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 3, p. 733, doi. 10.1007/s00280-011-1756-z

By:

Chung, Vincent;
Heath, Elisabeth;
Schelman, William;
Johnson, Brendan;
Kirby, Lyndon;
Lynch, Kerlin;
Botbyl, Jeffrey;
Lampkin, Thomas;
Holen, Kyle

Publication type:

Article

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.

Published in:

2011

By:

Kolesar J;
Brundage RC;
Pomplun M;
Alberti D;
Holen K;
Traynor A;
Ivy P;
Wilding G;
Kolesar, Jill;
Brundage, Richard C;
Pomplun, Marcia;
Alberti, Dona;
Holen, Kyle;
Traynor, Anne;
Ivy, Percy;
Wilding, George

Publication type:

journal article

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 447, doi. 10.1007/s00280-010-1346-5

By:

Holen, Kyle;
Belani, Chandra;
Wilding, George;
Ramalingam, Suresh;
Volkman, Jennifer;
Ramanathan, Ramesh;
Vasist, Lakshmi;
Bowen, Carolyn;
Hodge, Jeffrey;
Dar, Mohammed;
Ho, Peter

Publication type:

Article

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) in cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 393, doi. 10.1007/s00280-010-1331-z

By:

Kolesar, Jill;
Brundage, Richard;
Pomplun, Marcia;
Alberti, Dona;
Holen, Kyle;
Traynor, Anne;
Ivy, Percy;
Wilding, George

Publication type:

Article

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 5, p. 973, doi. 10.1007/s00280-010-1250-z

By:

Choi, Brian S.;
Alberti, Dona B.;
Schelman, William R.;
Kolesar, Jill M.;
Thomas, James P.;
Marnocha, Rebecca;
Eickhoff, Jens C.;
Ivy, S. Percy;
Wilding, George;
Holen, Kyle D.

Publication type:

Article

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy.

Published in:

Cancer Chemotherapy & Pharmacology, 2010, v. 65, n. 4, p. 775, doi. 10.1007/s00280-009-1084-8

By:

LoConte, Noelle K.;
Smith, Maureen;
Alberti, Dona;
Bozeman, Jeffrey;
Cleary, James F.;
Setala, Ashley N.;
Wodtke, Geoff;
Wilding, George;
Holen, Kyle D.

Publication type:

Article

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 1, p. 79, doi. 10.1007/s00280-008-0845-0

By:

Kolesar, Jill;
Wei Huang;
Eickhoff, Jens;
Hahn, Kristine;
Alberti, Dona;
Attia, Steven;
Schelman, William;
Holen, Kyle;
Traynor, Anne;
Ivy, Percy;
Wilding, George

Publication type:

Article

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 1, p. 45, doi. 10.1007/s00280-008-0844-1

By:

Attia, Steven;
Morgan-Meadows, Sherry;
Holen, Kyle D.;
Bailey, Howard H.;
Eickhoff, Jens C.;
Schelman, William R.;
Traynor, Anne M.;
Mulkerin, Daniel L.;
Campbell, Toby C.;
McFarland, Thomas A.;
Huie, Michael S.;
Cleary, James F.;
Tevaarwerk, Amye J.;
Alberti, Dona B.;
Wilding, George;
Liu, Glenn

Publication type:

Article

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 4, p. 727, doi. 10.1007/s00280-007-0656-8

By:

Schelman, William;
Morgan-Meadows, Sherry;
Bailey, Howard;
Holen, Kyle;
Thomas, James;
Eickhoff, Jens;
Brandon, Heidi;
Oliver, Kate;
Alberti, Dona;
Wilding, George

Publication type:

Article

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.

Published in:

Journal of Neuro-Oncology, 2017, v. 131, n. 1, p. 105, doi. 10.1007/s11060-016-2275-x

By:

Chabot, Pierre;
Hsia, Te-Chun;
Ryu, Jeong-Seon;
Gorbunova, Vera;
Belda-Iniesta, Cristobal;
Ball, David;
Kio, Ebenezer;
Mehta, Minesh;
Papp, Katherine;
Qin, Qin;
Qian, Jane;
Holen, Kyle;
Giranda, Vince;
Suh, John

Publication type:

Article

Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Published in:

Journal of Neuro-Oncology, 2015, v. 122, n. 2, p. 409, doi. 10.1007/s11060-015-1733-1

By:

Mehta, Minesh;
Wang, Ding;
Wang, Fen;
Kleinberg, Lawrence;
Brade, Anthony;
Robins, H.;
Turaka, Aruna;
Leahy, Terri;
Medina, Diane;
Xiong, Hao;
Mostafa, Nael;
Dunbar, Martin;
Zhu, Ming;
Qian, Jane;
Holen, Kyle;
Giranda, Vincent;
Curran, Walter

Publication type:

Article

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 6, p. 1539, doi. 10.1007/s10637-013-0029-6

By:

Schelman, William;
Traynor, Anne;
Holen, Kyle;
Kolesar, Jill;
Attia, Steven;
Hoang, Tien;
Eickhoff, Jens;
Jiang, Zhisheng;
Alberti, Dona;
Marnocha, Rebecca;
Reid, Joel;
Ames, Matthew;
McGovern, Renee;
Espinoza-Delgado, Igor;
Wright, John;
Wilding, George;
Bailey, Howard

Publication type:

Article

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 943, doi. 10.1007/s10637-012-9916-5

By:

LoConte, Noelle;
Holen, Kyle;
Schelman, William;
Mulkerin, Daniel;
Deming, Dustin;
Hernan, Hilary;
Traynor, Anne;
Goggins, Timothy;
Groteluschen, David;
Oettel, Kurt;
Robinson, Emily;
Lubner, Sam

Publication type:

Article

A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors.

Published in:

Investigational New Drugs, 2012, v. 30, n. 3, p. 1088, doi. 10.1007/s10637-011-9653-1

By:

Holen, Kyle;
DiPaola, Robert;
Liu, Glenn;
Tan, Antoinette;
Wilding, George;
Hsu, Karl;
Agrawal, Nancy;
Chen, Cong;
Xue, Lingling;
Rosenberg, Elizabeth;
Stein, Mark

Publication type:

Article

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2012, v. 30, n. 1, p. 387, doi. 10.1007/s10637-010-9532-1

By:

Kim, George;
Mahoney, Michelle;
Szydlo, Daniel;
Mok, Tony;
Marshke, Robert;
Holen, Kyle;
Picus, Joel;
Boyer, Michael;
Pitot, Henry;
Rubin, Joseph;
Philip, Philip;
Nowak, Anna;
Wright, John;
Erlichman, Charles

Publication type:

Article

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Published in:

Investigational New Drugs, 2011, v. 29, n. 6, p. 1475, doi. 10.1007/s10637-010-9474-7

By:

Shah, Manish;
Power, Derek;
Kindler, Hedy;
Holen, Kyle;
Kemeny, Margaret;
Ilson, David;
Tang, Laura;
Capanu, Marinela;
Wright, John;
Kelsen, David

Publication type:

Article

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Published in:

Investigational New Drugs, 2008, v. 26, n. 4, p. 369, doi. 10.1007/s10637-008-9123-6

By:

Steven Attia;
Jill Kolesar;
Michelle Mahoney;
Henry Pitot;
Daniel Laheru;
James Heun;
Wei Huang;
Jens Eickhoff;
Charles Erlichman;
Kyle Holen

Publication type:

Article

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.

Published in:

Investigational New Drugs, 2008, v. 26, n. 3, p. 241, doi. 10.1007/s10637-008-9118-3

By:

Chan, Emily;
Mulkerin, Daniel;
Rothenberg, Mace;
Holen, Kyle D.;
Lockhart, A. Craig;
Thomas, James;
Berlin, Jordan

Publication type:

Article

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Published in:

Investigational New Drugs, 2008, v. 26, n. 1, p. 45, doi. 10.1007/s10637-007-9083-2

By:

Kyle Holen;
Leonard Saltz;
Ellen Hollywood;
Konrad Burk;
Axel-Rainer Hanauske

Publication type:

Article

A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.

Published in:

Oncologist, 2011, v. 16, n. 6, p. 835, doi. 10.1634/theoncologist.2011-0031

By:

Mohammed, Tabraiz A.;
Holen, Kyle D.;
Jaskula-Sztul, Renata;
Mulkerin, Daniel;
Lubner, Sam J.;
Schelman, William R.;
Eickhoff, Jens;
Chen, Herbert;
Loconte, Noelle K.

Publication type:

Article

A Preclinical and Clinical Study of Lithium in Low-Grade Neuroendocrine Tumors.

Published in:

Oncologist, 2011, v. 16, n. 4, p. 452, doi. 10.1634/theoncologist.2010-0323

By:

LUBNER, SAM J.;
KUNNIMALAIYAAN, MUTHUSAMY;
HOLEN, KYLE D.;
NING, LI;
NDIAYE, MARY;
LOCONTE, NOELLE K.;
MULKERIN, DANIEL L.;
SCHELMAN, WILLIAM R.;
CHEN, HERBERT

Publication type:

Article

Carcinoid Tumors.

Published in:

Oncologist, 2008, v. 13, n. 12, p. 1255, doi. 10.1634/theoncologist.2008-0207

By:

PINCHOT, SCOTT N.;
HOLEN, KYLE;
SIPPEL, REBECCA S.;
CHEN, HERBERT

Publication type:

Article

Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon Cancer.

Published in:

Cancer Investigation, 2006, v. 24, n. 1, p. 98, doi. 10.1080/07357900500449637

By:

Holen, Kyle D.

Publication type:

Article

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Published in:

Neuro-Oncology, 2018, v. 20, n. 6, p. 838, doi. 10.1093/neuonc/nox202

By:

Gan, Hui K.;
Reardon, David A.;
Lassman, Andrew B.;
Merrell, Ryan;
van den Bent, Martin;
Butowski, Nicholas;
Lwin, Zarnie;
Wheeler, Helen;
Fichtel, Lisa;
Scott, Andrew M.;
Gomez, Erica J.;
Fischer, JuDee;
Mandich, Helen;
Hao Xiong;
Ho-Jin Lee;
Munasinghe, Wijith P.;
Roberts-Rapp, Lisa A.;
Ansell, Peter J.;
Holen, Kyle D.;
Kumthekar, Priya

Publication type:

Article

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Published in:

Neuro-Oncology, 2017, v. 19, n. 7, p. 965, doi. 10.1093/neuonc/now257

By:

Reardon, David A.;
Lassman, Andrew B.;
van den Bent, Martin;
Kumthekar, Priya;
Merrell, Ryan;
Scott, Andrew M.;
Fichtel, Lisa;
Sulman, Erik P.;
Gomez, Erica;
Fischer, JuDee;
Ho-Jin Lee;
Munasinghe, Wijith;
Hao Xiong;
Mandich, Helen;
Roberts-Rapp, Lisa;
Ansell, Peter;
Holen, Kyle D.;
Gan, Hui K.

Publication type:

Article

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Published in:

2018

By:

Goss, Glenwood D.;
Vokes, Everett E.;
Gordon, Michael S.;
Gandhi, Leena;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Fischer, JuDee S.;
Chu, Katharine L.;
Ames, William W.;
Mittapalli, Rajendar K.;
Lee, Ho‐Jin;
Zeng, Jiewei;
Roberts‐Rapp, Lisa A.;
Loberg, Lise I.;
Ansell, Peter J.;
Reilly, Edward B.;
Ocampo, Christopher J.;
Holen, Kyle D.;
Tolcher, Anthony W.;
Lee, Ho-Jin

Publication type:

journal article

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Published in:

Cancer (0008543X), 2012, v. 118, n. 9, p. 2424, doi. 10.1002/cncr.26556

By:

Philip, Philip A.;
Mahoney, Michelle R.;
Holen, Kyle D.;
Northfelt, Donald W.;
Pitot, Henry C.;
Picus, Joel;
Flynn, Patrick J.;
Erlichman, Charles

Publication type:

Article

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 3, p. 661, doi. 10.1007/s00280-013-2242-6

By:

Kolesar, Jill;
Traynor, Anne;
Holen, Kyle;
Hoang, Tien;
Seo, Songwon;
Kim, KyungMann;
Alberti, Dona;
Espinoza-Delgado, Igor;
Wright, John;
Wilding, George;
Bailey, Howard;
Schelman, William

Publication type:

Article

A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors.

Published in:

Clinical Colorectal Cancer, 2011, v. 10, n. 1, p. 57, doi. 10.3816/CCC.2011.n.008

By:

Dennie, Trevor W.;
Fleming, Ronald A.;
Bowen, Carolyn J.;
Dar, Mohammed M.;
Alberti, Dona;
Oliver, Katherine;
Loconte, Noelle;
Mulkerin, Dan;
Holen, Kyle D.

Publication type:

Article

A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

Published in:

2011

By:

Dennie, Trevor W.;
Fleming, Ronald A.;
Bowen, Carolyn J.;
Dar, Mohammed M.;
Alberti, Dona;
Oliver, Katherine;
Loconte, Noelle;
Mulkerin, Dan;
Holen, Kyle D.

Publication type:

Journal Article

A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer.

Published in:

Clinical Colorectal Cancer, 2010, v. 9, n. 3, p. 157, doi. 10.3816/CCC.2010.n.021

By:

Lubner, Sam J.;
LoConte, Noelle K.;
Holen, Kyle D.;
Schelman, William;
Thomas, James P.;
Jumonville, Alcee;
Eickhoff, Jens C.;
Seo, Songwon;
Mulkerin, Daniel L.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Lee, Sze Ting;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.253146

By:

Hui K. Gan;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.253146

By:

Hui K. Gan;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.253146

By:

Hui K. Gan;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Sze Ting Lee;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.253146

By:

Gan, Hui K.;
Burge, Matthew;
Solomon, Benjamin;
Lee, Sze Ting;
Holen, Kyle D.;
Yumin Zhang;
Ciprotti, Marika;
Lee, F. T.;
Munasinghe, Wijith;
Fischer, JuDee;
Ansell, Peter;
Fox, Gerard;
Hao Xiong;
Reilly, Edward B.;
Humerickhouse, Rod;
Scott, Andrew M.

Publication type:

Article

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Published in:

Oncologist, 2016, v. 21, n. 7, p. 785, doi. 10.1634/theoncologist.2016-0060

By:

Jin, Ning;
Lubner, Sam J.;
Mulkerin, Daniel L.;
Rajguru, Saurabh;
Carmichael, Lakeesha;
Chen, Herb;
Holen, Kyle D.;
LoConte, Noelle K.

Publication type:

Article

Guillain-Barré Syndrome After Treatment With Sunitinib Malate?

Published in:

Oncology (08909091), 2008, v. 22, n. 1, p. 66

By:

Mulherin, Brian;
Loconte, Noelle K.;
Holen, Kyle D.

Publication type:

Article

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 3, p. 671, doi. 10.1007/s10637-015-0234-6

By:

Cleary, James;
Reardon, David;
Azad, Nilofer;
Gandhi, Leena;
Shapiro, Geoffrey;
Chaves, Jorge;
Pedersen, Michelle;
Ansell, Peter;
Ames, William;
Xiong, Hao;
Munasinghe, Wijith;
Dudley, Matt;
Reilly, Edward;
Holen, Kyle;
Humerickhouse, Rod

Publication type:

Article

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

Published in:

2015

By:

LoConte, Noelle;
Razak, Albiruni;
Ivy, Percy;
Tevaarwerk, Amye;
Leverence, Rachael;
Kolesar, Jill;
Siu, Lillian;
Lubner, Sam;
Mulkerin, Daniel;
Schelman, William;
Deming, Dustin;
Holen, Kyle;
Carmichael, Lakeesha;
Eickhoff, Jens;
Liu, Glenn

Publication type:

Journal Article

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 169, doi. 10.1007/s10637-014-0166-6

By:

LoConte, Noelle;
Razak, Albiruni;
Ivy, Percy;
Tevaarwerk, Amye;
Leverence, Rachael;
Kolesar, Jill;
Siu, Lillian;
Lubner, Sam;
Mulkerin, Daniel;
Schelman, William;
Deming, Dustin;
Holen, Kyle;
Carmichael, Lakeesha;
Eickhoff, Jens;
Liu, Glenn

Publication type:

Article

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Published in:

Investigational New Drugs, 2014, v. 32, n. 5, p. 937, doi. 10.1007/s10637-014-0110-9

By:

Cleary, James;
Lima, Caio;
Hurwitz, Herbert;
Montero, Alberto;
Franklin, Catherine;
Yang, Jianning;
Graham, Alison;
Busman, Todd;
Mabry, Mack;
Holen, Kyle;
Shapiro, Geoffrey;
Uronis, Hope

Publication type:

Article